Tenofovir disoproxil fumarate

Tenofovir disoproxil fumarate has been studied in 30 papers since 2017: 1 trial and 16 observational studies in people, 4 in animals, 2 in cells, 6 reviews; 18 in the past year. It is an approved medicine. The newest story, Oct 20, 2026: “Immune gene variants linked to virus control in aged macaques”.

InterventionApproved 2001

30 papers study it10 more mention it18 findingsUpdated

PubChemChEBI

5 new papers in 30 daysSee all 40 papers on tenofovir disoproxil fumarate

At a glance

Independent labs found the same change in people. 13 independent labs in 12 countries; 212 trials, none about aging, 80 with no results posted.

“Serum 25(OH)D, total calcium, phosphate, and magnesium levels did not differ between randomization arms at all postpartum visits.”
Serum 25-hydroxy vitamin D, calcium, phosphate, and magnesium levels in association with bone mineral density at the hip and lumbar spine in African breastfeeding women: a longitudinal evaluationBMC nutrition2026doi:10.1186/s40795-026-01450-w

1 of its findings points the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 13 independent labs in 12 countries
  • 1 finding against
  • 212 trials, none about aging, 80 with no results posted
  • Funders: Basic and Applied Basic Research Foundation of Guangdong Province and others
  • 58 of 212 trials sponsored by its developers
  • Human trial1
  • Humans16
  • Animals4
  • Cells2
  • In silico1

What did studies of tenofovir disoproxil fumarate find?

7

Studies of tenofovir disoproxil fumarate measured 7 outcomes, among them bone mineral density, serum 25-hydroxyvitamin D, calcium, phosphate, and magnesium and bone mineral density.

Bone mineral density

downin humans2

2 studies
  1. Tenofovir disoproxil fumarate decreases bone mineral density in PLWH.

    “Tenofovir disoproxil fumarate is known to induce proximal renal tubular dysfunction and hypophosphatemia, contributing to reduced BMD.”

    Reviewin PLWH

    Bone Health in People Living with HIV: From Pathophysiology to Practical Management

    Infection & chemotherapy

  2. Tenofovir disoproxil fumarate decreases bone mineral density in humans (as part of combined antiretroviral therapy).

    “cART, particularly tenofovir disoproxil fumarate (TDF), contributes to reduced BMD”

    Reviewas part of combined antiretroviral therapybonefemales

    Bone Loss and Fractures in Post-Menopausal Women Living with HIV: A Narrative Review

    Pathogens (Basel, Switzerland)

More on Bone mineral density

Serum 25-hydroxyvitamin D, calcium, phosphate, and magnesium

no changein humans1

1 study
  1. Tenofovir disoproxil fumarate showed no clear effect on serum 25-hydroxyvitamin D, calcium, phosphate, and magnesium in humans (Initiation during pregnancy versus deferral until breastfeeding cessation).

    “Serum 25(OH)D, total calcium, phosphate, and magnesium levels did not differ between randomization arms at all postpartum visits.”

    Human trialInitiation during pregnancy versus deferral until breastfeeding cessationTDF-containing PrEPThrough 74 weeks postpartumfemalesn = 521

    Serum 25-hydroxy vitamin D, calcium, phosphate, and magnesium levels in association with bone mineral density at the hip and lumbar spine in African breastfeeding women: a longitudinal evaluation

    BMC nutrition

More on Serum 25-hydroxyvitamin D, calcium, phosphate, and magnesium

Bone mineral density

downin humans1

1 study
  1. Tenofovir disoproxil fumarate is linked with lower bone mineral density in men living with HIV (-1.4% [-2.8%; -0.1]%).

    “and TDF-use with lower tibia cortical vBMD (-1.4% [-2.8%; -0.1%]).”

    Humansin men living with HIVtibiamales

    Sex-specific bone architectural deficits among older adults living with HIV: a cross-sectional study from Zimbabwe

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Trabecular bone score

downin humans1

1 study
  1. Tenofovir disoproxil fumarate is linked with lower trabecular bone score in people living with HIV on stable ART (123.1 vs. 129.8).

    “With >5 years TDF exposure (n = 28), degraded TBS prevalence was 82.1% vs. 40.0% in never-exposed (p = 0.001), alongside lower TBS (123.1 vs. 129.8, p < 0.001)”

    Humansin people living with HIV on stable ART>5 yearsn = 98

    Multimodal Bone Fragility Profiling in People Living with HIV: Trabecular Bone Score, Calcaneal Quantitative Ultrasound, and Sarcopenia Screening

    Medicina (Kaunas, Lithuania)

More on Trabecular bone score

Oxidative stress and ROS signaling

downin mice1

1 study
  1. Tenofovir disoproxil fumarate decreases oxidative stress and ROS signaling in mice (APAP-induced acute liver injury).

    “Both drugs increased TAC and decreased levels of TOS and MDA.”

    AnimalsAPAP-induced acute liver injury

    Protective effects of linagliptin and tenofovir disoproxil fumarate against APAP-induced acute liver injury: A biochemical, histological, and computational study

    Tissue & cell

More on Oxidative stress and ROS signaling

Acute liver injury

downin mice1

1 study
  1. Tenofovir disoproxil fumarate decreases acute liver injury in mice (APAP-induced acute liver injury).

    “In vivo analysis exhibited ameliorated liver injury with Lina and TDF, as evidenced by significantly lowered liver injury markers.”

    AnimalsAPAP-induced acute liver injuryliver

    Protective effects of linagliptin and tenofovir disoproxil fumarate against APAP-induced acute liver injury: A biochemical, histological, and computational study

    Tissue & cell

More on Acute liver injury

Bone fracture

no changein humans1

1 study
  1. Tenofovir disoproxil fumarate was not clearly linked with bone fracture in humans (chronic hepatitis B) (weighted sHR 0.99, 95% CI 0.56-1.73, p = 0.960).

    “the risk of incident fracture in TDF-treated patients was comparable in the first 24 months (weighted subdistribution hazard ratio [sHR] 0.99, 95% CI 0.56-1.73, p = 0.960)”

    Humanschronic hepatitis Bfirst 24 months

    Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B

    Journal of hepatology

More on Bone fracture

What is tenofovir disoproxil fumarate linked with?

8

Studies link tenofovir disoproxil fumarate with 8 measures, among them osteoporosis, bone mineral density and rapid kidney function decline.

Osteoporosis

upin humans2

2 studies
  1. Tenofovir disoproxil fumarate is linked with a higher risk of osteoporosis in humans (virologically suppressed PLWH).

    “In men, advanced age, rural residency, inadequate physical activity, prolonged glucocorticoid use, hypocalcaemia and TDF‐containing regimens were independent risk correlates.”

    Humansvirologically suppressed PLWHmales

    Sex-specific prevalence and factors associated with osteoporosis among older people living with HIV under long-term virological suppression in western China: A retrospective cross-sectional study

    Research SquarePreprint

  2. Tenofovir disoproxil fumarate is linked with a higher risk of osteoporosis in humans (OR = 210).

    “Tenofovir Disoproxil (OR = 210) and Adefovir (OR = 59) exhibited the strongest drug-related risk signals.”

    Humans

    Real-world identification of high-risk medications for drug-induced osteoporosis: a multi-method pharmacovigilance study based on FAERS with WHO Vigibase validation

    Frontiers in endocrinology

More on Osteoporosis

Bone mineral density

downin humans2

2 studies
  1. Tenofovir disoproxil fumarate is associated with bone mineral density in humans (exposure >60 months in women living with HIV) (adjusted prevalence ratio 3.358; p = 0.028).

    “factors associated with low bone mineral density were tenofovir disoproxil fumarate exposure >60 months (adjusted prevalence ratio 3.358; p = 0.028)”

    Humansexposure >60 months in women living with HIVbone>60 monthsfemalesn = 129

    Prevalence of low bone mineral density in women living with HIV and associated factors

    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry

  2. Tenofovir disoproxil fumarate is associated with bone mineral density in humans (HIV with suppressed viral load taking antiretroviral therapy).

    “There was a significant relationship found between HIV diagnosis time, ART usage duration, tenofovir disoproxil fumarate (TDF) use, TDF use in the past, total TDF usage time and decreased BMD.”

    HumansHIV with suppressed viral load taking antiretroviral therapybonemalesn = 211

    The Prevalence and Associated Factors of Reduced Bone Mineral Density (BMD) Among Men with Suppressed Viral Load Taking Antiretroviral Therapy

    Current HIV research

More on Bone mineral density

Rapid kidney function decline

upin humans1RR 1.33

1 study
  1. Tenofovir disoproxil fumarate is linked with a higher risk of rapid kidney function decline in humans (Older people with HIV receiving antiretroviral therapy) (RR 1.33 (95% CI 1.11–1.60) per doubling of exposure in years).

    “Longer cumulative exposure to tenofovir disoproxil fumarate (TDF) (relative risk (RR) = 1.33 (95%CI:1.11–1.60) per doubling of TDF exposure in years)”

    HumansOlder people with HIV receiving antiretroviral therapyPer doubling of cumulative exposure in yearsMedian follow-up of 2.95 yearsn = 500

    Annual change in estimated glomerular filtration rate and predictors of rapid kidney function decline among antiretroviral therapy-experienced older people with HIV in Uganda, sub-Saharan Africa: A cohort study

    Research SquarePreprint

Urinary albumin-to-creatinine ratio

upin humans1

1 study
  1. Tenofovir disoproxil fumarate is associated with urinary albumin-to-creatinine ratio in humans (people living with HIV receiving TDF-based antiretroviral therapy).

    “Cumulative TDF exposure correlated positively with UACR (P = 0.001).”

    Humanspeople living with HIV receiving TDF-based antiretroviral therapy

    Five-year cumulative TDF exposure is associated with CKD in people living with HIV: a propensity score-matched study supporting UACR-based renal screening

    Frontiers in cellular and infection microbiology

More on Urinary albumin-to-creatinine ratio

Chronic kidney disease

upin humans1OR 1.58

1 study
  1. Tenofovir disoproxil fumarate is associated with chronic kidney disease in humans (Chinese people living with HIV receiving TDF-based antiretroviral therapy) (OR 1.580, 95% CI 1.023–2.440; >5 years versus <2 years).

    “relative to <2 years' exposure, longer durations conferred increased odds (>5 years: OR 1.580, 95% CI 1.023–2.440, P = 0.039).”

    HumansChinese people living with HIV receiving TDF-based antiretroviral therapy>5 years versus <2 years

    Five-year cumulative TDF exposure is associated with CKD in people living with HIV: a propensity score-matched study supporting UACR-based renal screening

    Frontiers in cellular and infection microbiology

More on Chronic kidney disease

Hypophosphatemia

upin humans1

1 study
  1. Tenofovir disoproxil fumarate is associated with hypophosphatemia in humans (People living with HIV on antiretroviral therapy).

    “Regimens containing tenofovir disoproxil fumarate showed an increased risk of hypophosphatemia, although logistic regression did not confirm significance at the 5% level.”

    HumansPeople living with HIV on antiretroviral therapy

    Evaluation of serum phosphorus levels and their relation with the development of osteoporosis in people living with HIV/AIDS

    Revista da Associacao Medica Brasileira (1992)

More on Hypophosphatemia

Renal tubular injury

upin humans1

1 study
  1. Tenofovir disoproxil fumarate raises the risk of renal tubular injury in PLWH.

    “potential detrimental effects of tenofovir-based ART regimens in causing renal tubular injury”

    Reviewin PLWH

    A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy

    Frontiers in medicine

Bone fracture

upin humans1

1 study
  1. Tenofovir disoproxil fumarate is linked with a higher risk of bone fracture in humans (chronic hepatitis B) (weighted sHR 1.80, 95% CI 1.11-2.93, p = 0.019).

    “increased after month 24 (weighted sHR 1.80, 95% CI 1.11-2.93, p = 0.019)”

    Humanschronic hepatitis Bafter month 24

    Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B

    Journal of hepatology

More on Bone fracture

Has tenofovir disoproxil fumarate been tested in people?

0 of 212 about aging

Yes: 1 trial and 16 observational studies in people have been published, and 211 trials are registered.

Approved

  • FDA Viread

    Oct 26, 2001Hepatitis B, Chronic, HIV-1 Infection, Human Immunodeficiency Virus-type 1 Infection, hepatitis b virus, chronic hepatitis b in adults and pediatric patients

  • EMA Viread

    Feb 4, 2002Hepatitis B, Chronic, HIV Infections, Hepatitis B Infection, HIV-1 Infection, hepatitis b virus

  • FDA Viread

    Jan 18, 2012Hepatitis B, Chronic, HIV-1 Infection, Human Immunodeficiency Virus-type 1 Infection, hepatitis b virus, chronic hepatitis b in adults and pediatric patients

  • EMA Tenofovir disoproxil Zentiva

    Sep 15, 2016HIV Infections, Hepatitis B, Chronic, Hepatitis B Infection, Hepatitis B, hepatitis b virus

  • EMA Tenofovir disoproxil Viatris (previously Tenofovir disoproxil Mylan)

    Dec 8, 2016HIV Infections, Hepatitis B, Chronic, HIV-1 Infection, Hepatitis B Infection, Hepatitis B, hepatitis b virus

Repurposing

All 34

In trials

  • Medication adherence

    Phase 4Results posted4 trials

  • HIV-2 infection

    Phase 4Results posted2 trials

  • Risk-Taking

    Phase 4Results posted2 trials

  • Body weight changes

    Phase 4Status unknown1 trial

  • Hbv

    Phase 4Completed1 trial

  • Pharmacokinetic of tenofovir in healthy subjects

    Phase 4Completed1 trial

All 13

Stopped

  • NCT00356616TerminatedHIV infection

    terminated

  • NCT00679926TerminatedHIV infection

    Lack of enrollment

  • NCT00998582TerminatedHIV infection

    Low enrollment

  • NCT01602822TerminatedHIV

    Grade 3 elevation in liver function tests

  • NCT02447016TerminatedHIV

    no more participants taking atripla

  • NCT03563742TerminatedHuman immunodeficiency virus infection

    High SF rate (less treatment-naïve subjects \& subjects with viral load \<100000). Reevaluation in scientific position in India after internal discussion.

All 7

Who is developing tenofovir disoproxil fumarate?

3 companies: Samjin Pharmaceutical, Gilead Sciences and Merck Sharp & Dohme.

Companies
  • Samjin PharmaceuticalPhase 4chronic hepatitis B
  • Gilead SciencesPhase 3chronic hepatitis B, pre exposure prophylaxis of hiv infection
  • Merck Sharp & DohmePhase 3HIV-1 infection

Trial sponsors

Latest

Dec 2025: 3Jan 2026: 1Feb 2026: 3Mar 2026: 2Apr 2026: 2May 2026: 1Jun 2026: 1Jul 2026: 0Aug 2026: 1Sep 2026: 2Oct 2026: 3Nov 2026: 221 papers in 12 months
Journal of Immunology

Immune gene variants linked to virus control in aged macaques

In an infection experiment, rhesus macaques aged 17–23 with protective immune gene variants had lower blood virus levels through 70 days than those without.In an infection experiment, rhesus macaques aged 17–23 with protective immune gene variants had lower blood virus levels through 70 days than those without.

Animal study · 16 animalsBlood and immune system

See all 40 papers on tenofovir disoproxil fumarate